Education
About Us
Working with TipRanks
Follow Us
uniQure N.V. (QURE)
NASDAQ:QURE
QURE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.45 - $19.18
Previous CloseN/A
Volume1.49M
Average Volume (3M)1.15M
Market Cap
$758.81M
Enterprise Value$909.01M
Total Cash (Recent Filing)$376.97M
Total Debt (Recent Filing)$66.70M
Price to Earnings (P/E)―
Beta1.57
Next Earnings
Oct 29, 2025EPS Estimate
-0.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.69
Shares Outstanding54,866,930
10 Day Avg. Volume1,520,880
30 Day Avg. Volume1,154,577
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue63.40
Enterprise Value/Gross Profit76.75
Enterprise Value/Ebitda-6.25
Forecast
1Y Price Target
$69.00Price Target Upside45.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Bulls Say, Bears Say
Bulls Say
Efficacy Of AMT-130UniQure announced positive top-line results from the pivotal Phase I/II study of AMT-130 in Huntington’s disease, showing a 75% slowing of disease progression.
Market OpportunityThe data suggests a larger market opportunity and a higher probability of approval for AMT-130.
Regulatory ProgressThere is strong alignment with the FDA, and QURE has received breakthrough therapy designation for AMT-130's earlier data.
Bears Say
Adverse EventsThere were 2 SAEs of stroke and diplopia considered not related and 1 SAE of leptomeningeal enhancement considered possibly related to treatment.
Clinical Development RisksRisks include clinical development risk tied to AMT-130, commercialization risk, reimbursement risk, capital markets and dilution risk, pricing risk, and clinical trial risk.
uniQure News
QURE FAQ
What was uniQure N.V.’s price range in the past 12 months?
uniQure N.V. lowest stock price was $4.45 and its highest was $19.18 in the past 12 months.
What is uniQure N.V.’s market cap?
uniQure N.V.’s market cap is $758.81M.
When is uniQure N.V.’s upcoming earnings report date?
uniQure N.V.’s upcoming earnings report date is Oct 29, 2025 which is in 33 days.
How were uniQure N.V.’s earnings last quarter?
uniQure N.V. released its earnings results on Jul 29, 2025. The company reported -$0.69 earnings per share for the quarter, beating the consensus estimate of -$0.895 by $0.205.
Is uniQure N.V. overvalued?
According to Wall Street analysts uniQure N.V.’s price is currently Undervalued.
Does uniQure N.V. pay dividends?
uniQure N.V. does not currently pay dividends.
What is uniQure N.V.’s EPS estimate?
uniQure N.V.’s EPS estimate is -0.93.
How many shares outstanding does uniQure N.V. have?
uniQure N.V. has 54,866,930 shares outstanding.
What happened to uniQure N.V.’s price movement after its last earnings report?
uniQure N.V. reported an EPS of -$0.69 in its last earnings report, beating expectations of -$0.895. Following the earnings report the stock price went down -8.678%.
Which hedge fund is a major shareholder of uniQure N.V.?
Currently, no hedge funds are holding shares in QURE
uniQure Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$69.00 (45.26% Upside)
$69.00 (45.26% Upside)
Blogger Sentiment
Bullish
QURE Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 25.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $20.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
824.12%
12-Months-Change
Fundamentals
Return on Equity
-427.47%
Trailing 12-Months
Asset Growth
-19.97%
Trailing 12-Months
Company Description
uniQure N.V.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
QURE Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant regulatory and clinical advancements, particularly with AMT-130 and AMT-260, and a strong financial position. However, these positives were tempered by a notable decline in revenue and increased R&D expenses.View all QURE earnings summariesQURE Stock 12 Month Forecast
Average Price Target
$69.00
▲(45.26% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Spyre Therapeutics
―
Intellia Therapeutics
―
CureVac
―
Day One Biopharmaceuticals
―
Ownership Overview
2.52% Insiders
9.77% Mutual Funds
0.07% Other Institutional Investors
82.37% Public Companies and
Individual Investors